H.C. Wainwright lowered the firm’s price target on Innate Pharma (IPHA) to $11 from $11.50 and keeps a Buy rating on the shares. The firm postponed the U.S. launch of IPH6101 to 2029 from previously estimated 2027 and EU launch to 2030 from 2028.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPHA: